BioLife Solutions(BLFS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for 2025 grew 29% to $96 million, landing at the high end of guidance, which was raised twice in the second half of the year [5][13] - Adjusted EBITDA increased to $25 million or 26% of revenue, up from $13 million or 18% in 2024 [5][18] - Adjusted net income for Q4 was $1.9 million, compared to an adjusted net loss of $0.1 million in Q4 of the prior year [17] Business Line Data and Key Metrics Changes - In Q4, total revenue reached $24.8 million, increasing 20% year-over-year, primarily driven by the biopreservation media (BPM) franchise [6][13] - BPM product line accounted for approximately 85% of total revenue, with commercial BPM customers accounting for nearly 50% of revenue, up from the low 40s range in 2024 [6][14] - The hPL media business was flat year-over-year due to import restrictions in China, which have since been lifted [14] Market Data and Key Metrics Changes - BioLife's BPM products are embedded in 16 approved therapies and utilized in over 250 commercially sponsored CGT trials in the U.S., representing over 70% market share [7] - Anticipation of up to 5 unique therapy approvals over the next 12 months, along with 1 new indication and at least 1 geographic expansion [9] Company Strategy and Development Direction - The company aims to drive sustainable, profitable growth and shareholder value with a streamlined portfolio centered on market-leading consumables [4] - A strategic distribution and product development agreement with Qkine Limited was established to expand the product offering into cytokines, complementing the emerging hPL product line [10][11] - The company is focused on increasing adoption of non-BPM products and driving operational excellence across the organization [71] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the cell and gene therapy (CGT) market, supported by favorable regulatory developments and increased strategic investments by large pharma [12] - For 2026, the company issued guidance of total revenue between $112 million and $115 million, reflecting growth of 17%-20% [11][20] - Expected full year positive GAAP net income for the first time in many years, along with further expansion of adjusted EBITDA margins compared to 2025 [21] Other Important Information - The company implemented ERP manufacturing modules in February 2026, enhancing automated processes and controls for manufacturing and accounting functions [13] - Cash and marketable securities balance at December 31, 2025, was $120.2 million, an increase from $105.4 million at December 31, 2024 [19] Q&A Session Summary Question: Guidance assumptions between commercial and clinical - Management expects commercial customers to represent 50%-55% of revenue in 2026, with no significant uptick seen in clinical activity levels yet [25][26] Question: Bag yield impact on margins - The bag yield issue was about a 2 to 3-point headwind on gross margin in the second half of 2025, with solutions expected to be implemented by Q4 2026 [26][27] Question: Exposure to CAR T market - Over 80% of commercial exposure is related to CAR T therapies, with patient access being a key constraint to overall adoption [32] Question: Cross-selling initiative success - The growth rate of non-BPM tools is expected to outpace BPM, with metrics on customer usage of multiple products being a future goal [40][41] Question: Qkine partnership details - The partnership with Qkine is seen as a long-term strategic move, with revenue expected to materialize in the future [46][47]